Clinical Trials Logo

Liver Neoplasms clinical trials

View clinical trials related to Liver Neoplasms.

Filter by:

NCT ID: NCT05804799 Completed - Liver Cancer Clinical Trials

Liver CT Dose Reduction With Deep Learning Based Reconstruction

Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

A deep learning-based de-noising (DLD) reconstruction algorithm (ClariCT.AI) has the potential to reduce image noise and improve image quality. This capability of the CliriCT.AI program might enable dose reduction for contrast-enhanced liver CT examination. In this prospective multicenter study, whether the ClariCT.AI program can reduce the noise level of low-dose contrast-enhanced liver CT (LDCT) data and therefore, can provide comparable image quality to the standard dose of contrast-enhanced liver CT (SDCT) images will be evaluated. The aim of this study is to compare image quality and diagnostic capability in detecting malignant tumors of LDCT with DLD to those of SDCT with MBIR using the predefined non-inferiority margin.

NCT ID: NCT05643833 Completed - Cancer of Liver Clinical Trials

Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma

Start date: January 1, 2021
Phase:
Study type: Observational

This is a large-scale study in China to provide evidence and insights in the role of gender in LT for HCC by analyzing the data of 3769 recipients with HCC registered in the China Liver Transplant Registry.

NCT ID: NCT05540925 Completed - Liver Cancer Clinical Trials

Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer

Start date: January 1, 2022
Phase:
Study type: Observational

Tumor staging system based on clinicopathological charactertics has been used to guide treatment decisions. However, therapeutic outcomes of "early-stage" hepatocellular carcinoma (HCC) differs significantly, which strongly suggests the requirement for a re-staging of early HCC to inform treatment selection more precisely. Microvascular invasion (MVI) reflects malignant biological characteristics of early HCC, and has a potential role of guiding treatment selection. As such, the objective of this study is to investigate preoperative MVI prediction based on MVI-related genomic signatures of cell-free circulating tumor DNA (ctDNA) to establish a re-staging of early HCC. The investigators have detected 37 mutant genes associated with MVI in HCC tumor tissues. In this study, the investigators will design a gene panel based on these mutant genes to perform targeted gene sequencing on preoperatively collected ctDNA to identify genomic signatures associated with MVI. A nomogram to predict MVI before treatment will be generated by incorporating these genomic signatures. Based on a calculated optimal cut-off value of the nomogram, early HCC patients can be re-staged into subpopulations based on the nomogram-predicted risks of MVI. This study will develop a re-staging system of early HCC based on tumor biological charactertics, which is expected to accurately and individually guide treatment decisions and improve long-term survival outcomes.

NCT ID: NCT05532319 Completed - Liver Cancer Clinical Trials

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC

FRONT-1
Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.

NCT ID: NCT05495529 Completed - Neoplasm Metastasis Clinical Trials

Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors

Start date: January 1, 2013
Phase:
Study type: Observational

This study aims to analyse retrospectively the feasibility, the safety, and the efficiency, of biliary or digestive protection with room air interposition for thermal ablation of central liver tumors with high iatrogenic risk. Thermal ablation is a mini-invasive and curative treatement of liver tumors. However, it requires to be carefull about surrunding organs, such as digestive structures or central biliary tree, which can be injured if not insulated. The technique of gas interposition to protect adjacent gut is already known and validated with carbonic gas. Nevertheless, resorption of this gas is very fast, making its use tricky to keep a correct insulation during the whole thermal ablation process. Room air interposition is easy to use and can offer a slow resorption speed. Furthermore no datas are available concerning the use of room air whatever the organ protected, and the protection of central biliary tree whatever the gas used.

NCT ID: NCT05475054 Completed - Obesity Clinical Trials

Impact of Minimally Invasive and Open Liver Surgery in Different BMI-classes

MILSOBES
Start date: December 1, 2020
Phase:
Study type: Observational

Despite the worldwide increase of both obesity and use of minimally invasive liver surgery(MILS), evidence regarding the safety and eventual benefits of MILS in obese patients is scarce. The aim of this study is therefore to compare the outcomes of non-obese and obese patients(BMI 18.5-29.9 and BMI≥30, respectively) undergoing MILS and OLS, and to assess trends in MILS use among obese patients. In this retrospective cohort study, patients operated at 20 hospitals in eight countries(2009-2019) will be included and the characteristics and outcomes of non-obese and obese patients will be compared. Thereafter, the outcomes of MILS and OLS were compared in both groups after propensity-score matching(PSM). Changes in the adoption of MILS during the study period will be investigated.

NCT ID: NCT05462470 Completed - Colorectal Cancer Clinical Trials

Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis

Start date: January 1, 2008
Phase:
Study type: Observational

For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving effective conversion therapy, disease relapse after conversion hepatectomy is common due to the extensive tumor load. Yet, few studies have focused on the assessment and management of relapse after conversion hepatectomy for IU-CRLM. This study aimed to investigate the impact of surgical management for relapse after conversion hepatectomy in IU-CRLM.

NCT ID: NCT05445973 Completed - Ultrasonography Clinical Trials

Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Contrast-enhanced ultrasonography (CEUS)-CT/MRI fusion imaging substantially improved the visibility of small tumors that were inconspicuous on both US and US-CT/MRI fusion imaging, contributing to successful percutaneous radiofrequency ablation.

NCT ID: NCT05370001 Completed - Liver Tumor Clinical Trials

Endotracheal Tube Size Effect on the Carbon Dioxide Washout During Jet Ventilation

Start date: June 13, 2022
Phase: N/A
Study type: Interventional

High Frequency Jet Ventilation (HFJV) can be used in liver tumour ablation to minimise breathing related movements. The jet cannula is placed freely inside an endotracheal tube (ETT) and the outflow of air is passive, moving out in the interspace between the jet cannula and the inner walls of the ETT. This study aims to investigate whether the tube size can influence the washout of carbon dioxide using two different sizes of ETT's.

NCT ID: NCT05361252 Completed - Fluid Management Clinical Trials

Stroke Volume Variation-guided Fluid Infusion in Major Liver Tumour Resection

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Studies have demonstrated that the rate of change in stroke volume variation (SVV) can be used to determine the volume of body fluids during major abdominal surgery. Anaesthesiologists can use SVV as a guide for the appropriate administration of intraoperative fluids to improve postoperative prognoses. Liver surgery is a major abdominal operation, and the amount of blood lost is typically higher than that during other general abdominal surgeries. Blood loss is positively correlated with the intraoperative fluid infusion volume, and greater blood loss is associated with more postoperative complications. Additionally, comorbid liver disease or cirrhosis can increase the complexity of liver tumour resection, causing difficulty in assessing intravascular volume and determining the appropriate intraoperative infusion volume.